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Recent Advances in Chest Medicine B leeding from the lung originates from the bronchial vessels, the pulmonary vessels, or the microcirculation of the lung. Bleeding of bronchial origin is usually a result of bronchiectasis or endobronchial malignancy. Pulmonary hemorrhage originating from the small, medium, and large pulmonary vessels is most commonly due to systemic vasculitis, which can also involve the microcirculation. Vasculitides involving the microvasculature is known as pulmonary capillaritis. Diffuse alveolar hemorrhage (DAH) is a clinicopathologic syndrome describing the accumulation of intraalveolar RBCs originating from the alveolar capillaries. All causes of DAH have the common denominator of an injury to the alveolar microcirculation. The clinical syndrome includes hemoptysis, anemia, diffuse radiographic pulmonary infi ltrates, and hypoxemic respiratory failure, which can be severe. DAH is associated with a number of clinical entities and several histologic subtypes. The most common underlying histology of DAH is of a small vessel vasculitis known as pulmonary capillaritis, usually seen with seropositive systemic vasculitides, or a connective tissue disorder, bland pulmonary hemorrhage, and diffuse alveolar damage due to a number of injuries including drugs, coagulation disorders, and infections. Pulmonary capillaritis may also be a small vessel vasculitis limited to the lung. BAL confi rms the clinical diagnosis of DAH; however, a surgical lung biopsy may be required to confi rm the underlying histology. In general, surgical lung biopsy is considered if DAH is associated with negative serology and not a part of a systemic disease. Treatment is directed at the underlying diagnosis and typically includes corticosteroids, immunosuppressive agents, and occasionally plasmapheresis.
Definition
DAH is recognized by the clinical constellation of hemoptysis, anemia, diffuse radiographic pulmonary infi ltrates, and hypoxemic respiratory failure. The underlying histopathology of DAH includes the presence of intraalveolar RBCs and fi brin and the eventual accumulation of hemosiderin-laden macrophages, which may take up to 48 to 72 h to accumulate. Of the histologies that are associated with DAH (pulmonary capillaritis, bland pulmonary hemorrhage, diffuse alveolar damage, and miscellaneous histology) pulmonary capillaritis is the most common.
Diffuse alveolar hemorrhage (DAH) is often a catastrophic clinical syndrome causing respiratory failure. Recognition of DAH often requires BAL as symptoms are nonspecifi c, hemoptysis is absent in up to one-third of patients, and radiographic imaging is also nonspecifi c and similar to other acute alveolar fi lling processes. Once the diagnosis is established, the underlying cause must be established in order to initiate treatment. This review discusses the diagnosis of the underlying histologies and the clinical entities that are responsible for DAH as well as treatment options.
CHEST 2010; 137(5):1164-1171 (13%), idiopathic pulmonary hemosiderosis (IPH) (13%), collagen vascular diseases (13%), and microscopic polyangiitis (MPA) (9%). In another series, isolated pauciimmune pulmonary capillaritis was the most common cause of DAH associated with capillaritis. 6 In recipients of hematopoietic stem cell transplantation, DAH was reported to occur in 5% of 3,806 patients. 7 Clinical Presentation and Diagnosis DAH appears at any age and often with an established associated disease. DAH may also be the initial manifestation of an underlying systemic disease. The cardinal sign of DAH, hemoptysis, may be a dramatic event or evolve over days to weeks; however, it may be initially absent in up to 33% of DAH cases. The natural course is unpredictable and varies in severity but always should be considered a potentially lifethreatening event. The symptoms of DAH, other than hemoptysis, are nonspecifi c and include fever, chest pain, cough, and dyspnea. Nonpulmonary signs and symptoms are those that accompany the underlying systemic disease. In addition to history, physical examination, and routine laboratory studies, directed serologic testing for connective tissue disease and systemic vasculitis is useful for establishing the di agnosis ( Table 2 ). In up to one-third of patients with DAH, hemoptysis is absent and the diagnosis is established after sequential BAL reveals worsening RBC counts. 8 Moreover, a falling hematocrit should alert the clinician to the possibility of DAH. The chest radiograph fi ndings are nonspecifi c and consist of an alveolar fi lling process that can be a patchy, focal, or diffuse alveolar fi lling process ( Fig 2 ) . Chest CT scans confi rm the chest radiographic fi ndings and more accurately defi ne the extent of disease. Flexible bronchoscopy should be performed to establish the clinical diagnosis of DAH and to exclude infections. Progressively hemorrhagic BAL found in serial samples is diagnostic of DAH but not the underlying cause. Surgical lung biopsy may be required to establish the cause if serologic testing or clinical history is unrevealing. Transbronchial biopsies are usually insuffi cient. With recurrent episodes of DAH, interstitial fi brosis or an obstructive lung disease most compatible with emphysema can evolve. 9, 10 Specific Disorders Associated With DAH
Isolated Pauciimmune Pulmonary Capillaritis
Isolated pauciimmune pulmonary capillaritis is a small-vessel vasculitis that is confi ned to the lung and without clinical or serologic features of an associated systemic disease. In a series of 29 cases of biopsy-confi rmed Pulmonary capillaritis has a unique histopathologic appearance consisting of an interstitial neutrophilic predominant infi ltration, fi brinoid necrosis of the alveolar and capillary walls, and leukocytoclasis. 1 The infi ltrating neutrophils undergo cytoclasis, nuclear debris accumulates within the interstitium, and there is a subsequent loss of the integrity of the alveolarcapillary basement membrane ( Fig 1 ) . It is the disruption of the alveolar-capillary basement membranes that results in the accumulation of RBCs in alveolar spaces. There is a distinction between pulmonary capillaritis and pulmonary vasculitis. Pulmonary vasculitis refers to infl ammation of the lung vessels of any size, whereas pulmonary capillaritis is confi ned to the microcirculation of the lung (alveolar capillaries, arterioles, and venules). However, both may be seen in systemic vasculitides and the connective tissue diseases.
Recently, there has been an effort to change the eponym of Wegener granulomatosis (WG) to a more scientifi c nomenclature of antineutrophilic cytoplasmic autoantibodies (ANCA)-associated granulomatous vasculitis. [2] [3] [4] This is not the fi rst time that an eponym has undergone a change (eg, Loeffl er Syndrome and simple pulmonary eosinophilia). 5 Although the suggestion to develop an alternative name for WG may have evolved after the association of Dr Wegener and the Nazi regime, it is our opinion that the alternative should be used because it serves to describe the pathology, and eponyms do not describe the disease process.
Etiology
Injury to the alveolar microcirculation resulting in DAH may be localized to the lung (inhalation injuries, diffuse alveolar damage) or associated with a systemic disorder (vasculitis or connective tissue disease). The causes of DAH are listed in Table 1 . There is a spectrum of disorders associated with DAH, but no prospective studies estimate its relative frequency. A review of 34 cases of histopathologically confi rmed DAH indicated that capillaritis occurred in 88% of the cases. In one report, the most common clinical cause of DAH was WG (32%), followed by Goodpasture syndrome is unknown but is reported to occur most commonly before the age of 30 years. In the pediatric population the incidence is reported to be 0.24 in 1 million. 13 The histology lacks evidence of capillaritis and the alveolar basement membranes are thickened but remain intact. Recurrent episodes of DAH lead to release of iron into the lung resulting in an abundance of hemosiderin-laden macrophages. 11, 14 In advanced cases of IPH, the lungs develop a distinctive brown color due to the abundance of hemosiderin and have varying degrees of consolidation and fi brosis. The cause and pathogenesis is unknown; however, an immune process may be involved as IPH appears to respond to immunosuppressant therapy. Although IPH was included as a syndrome with DAH, it should be noted that it is a rare entity distinct in histology from other causes of DAH resulting from the microcirculation.
ANCA-Associated Granulomatous Vasculitis
ANCA-associated granulomatous vasculitis is a systemic vasculitis characterized by granulomatous infl ammation of the upper and lower respiratory tract, necrotizing vasculitis, and the presence of ANCA. The ANCA associated with ANCA-associated granulomatous vasculitis is an antibody directed against cytoplasmic proteinase 3 (PR3). 15 Demographic data obtained from the WG Etanercept Trial varied between the patients with limited vs severe disease. Patients with DAH were defi ned as having severe disease, were older (mean age of 50 6 16 vs 41 6 16 years), and were more likely to be men. DAH was identifi ed in 25% of the patients with more severe disease. 16 The pathogenesis of PR3-ANCA-positive vasculitis involves the cellular immune pathways resulting in granulomatous inflammation. 15 The percentage expression of PR3 on the surface of neutrophils in patients with ANCA-associated granulomatous vasculitis correlates with higher rates of relapse. 17 A retrospective analysis found rising titers of cytoplasmic-ANCA to have high sensitivity and specifi city (93% and 97%, respectively) in predicting relapse or the presence of active disease. 18, 19 However, a recent prospective study had a specifi city of 75% and a sensitivity of 71% for predicting relapse using rising titers. 20 Patients with persistently high titers of PR3-ANCA after remission tend to have a higher risk of relapse than those who are ANCA negative. 21 Current treatment is concentrated for the induction of remission using corticosteroids and cyclophosphamide. Maintenance therapy after remission is achieved either with methotrexate or azathioprine. Recently rituximab, a chimeric anti-CD20 monoclonal antibody, has been shown to induce remission in patients with refractory ANCA-associated granulomatous vasculitis, but should pulmonary capillaritis, isolated pauciimmune pulmonary capillaritis was the most common cause of DAH. 11 Overall, patients with isolated pauciimmune pulmonary capillaritis tend to have a better prognosis when compared with DAH occurring in the setting of a systemic vasculitis or collagen vascular disease.
IPH
IPH is a rare syndrome in which repeated episodes of DAH occur resulting in chronic anemia and pulmonary fi brosis. 12 The incidence in the adult population patients who survive an episode of DAH their 1-year and 5-year survival is reduced to 82% and 68%, respectively. [26] [27] [28] MPA can be distinguished from ANCA-associated granulomatous vasculitis by serologically demonstrating a perinuclear-ANCA directed against neutrophil myeloperoxidase (MPO-ANCA). Unlike ANCA-associated granulomatous vasculitis, the level of MPO-ANCA titers is not associated with disease activity. 29 Recent animal studies suggest that MPO-ANCA, and to a lesser degree PR3-ANCA, may mediate disease by activating the alternative complement pathway, a self-sustaining pathway, and may lend new insight into the severity of disease in ANCApositive diseases. 30 Surgical lung biopsy is usually not not be considered as fi rst-line therapy in Wegenerassociated DAH. 22 Plasma exchange has also shown usefulness if instituted early in the disease course. [23] [24] [25] MPA MPA is a systemic vasculitis that is confi ned to the microvessels and is always associated with a focal segmental necrotizing glomerulonephritis. It is distinguished from ANCA-associated granulomatous vasculitis by the absence of upper airway involvement. DAH due to pulmonary capillaritis occurs in up to one-third of patients and represents the only pulmonary manifestation of MPA. DAH increases the mortality of MPA. In the acute setting, 30% of patients do not survive an episode of DAH; in those 
Other Connective Tissue Diseases
DAH with underlying pulmonary capillaritis is an infrequent occurrence in mixed connective tissue disease, rheumatoid arthritis, polymyositis, dermatomyositis, primary antiphospholipid syndrome, and scleroderma. [42] [43] [44] [45] [46] [47] [48] [49] [50] [51] [52] [53] [54] The DAH may be the presenting manifestation or complicate a preexisting disease. Treatment options are similar to those outlined for DAH in SLE.
Goodpasture Syndrome (Antiglomerular Basement Membrane Antibody Disease)
Goodpasture syndrome, also known as antiglomerular basement membrane antibody disease-associated DAH, is likely the result of autoantibodies directed against the NC1 domain of the a 3 chain of the basement membrane collagen type 4. 55 The clinical expression of the disease occurs only in the lungs and the kidneys. DAH is common in antiglomerular basement membrane disease, particularly in cigarette smokers. It is postulated that smoking mediates damage to the alveolar basement membrane, thus allowing the development of autoantibodies. 56, 57 Bland hemorrhage is the most common underlying histology, but pulmonary capillaritis is sometimes seen. 58 Patients with Goodpasture syndrome tend to be men in their 20s who also smoke. More than 90% of patients with Goodpasture disease have circulating antibasement membrane antibodies. In patients with negative circulating antibasement membrane antibodies, a lung or renal biopsy with immunofl uorescence revealing linear antibody deposition within the alveolar or glomerular basement membrane confi rms the diagnosis. 59 However, in up to 10% of patients with Goodpasture syndrome, DAH is present without renal involvement and is identical to isolated pulmonary capillaritis. Lung biopsy with immunofl uorescence studies distinguishes the two. 60, 61 Treatment with immunosuppression and plasma exchange has improved outcomes in these patients. 62 Rituximab, a chimeric anti-CD20 monoclonal antibody that has shown efficacy in the treatment of rheumatoid arthritis, should be considered in patients with ANCA-associated vasculitis that is refractory to standard therapy. 63, 64 Treatment with rituximab results in depletion of B cells that produce pathogenic autoantibodies and reduces the cellular interaction by decreasing both the production of cytokines that maintain mononuclear cells and the production of immune complex formations that help to sustain the disease. 65 
Lung Allograft Rejection
Pulmonary capillaritis as a form of acute lung transplant rejection was fi rst described in fi ve patients in necessary in patients with suspected DAH in the setting of ANCA-positive disease provided infection has been excluded. Treatment, as with ANCA-associated granulomatous vasculitis, is glucocorticoids, cyclophosphamide, and plasmapheresis, and is the recommended regimen for induction of remission. 31 Recombinant factor VIIa has been used to treat severe DAH in MPA with unremitting respiratory failure. The mechanism of factor VIIa treatment is the enhancement of thrombin generation on the surface of activated platelets at the sites of hemorrhage. 32 
Systemic Lupus Erythematosus
DAH occurs in 4% of patients with systemic lupus erythematosus (SLE) admitted to the hospital and pulmonary capillaritis is usually the underlying cause. 8 In an immunosuppressed patient with SLE, infectious pneumonia should be excluded as the cause of DAH. 33 In the majority of DAH associated with SLE, glomerulonephritis is also present, and in 80% the DAH occurs in patients with known SLE. 8 These are most often young females with a mean age of 27 years. The mortality had been previously reported to be as high as 50%; however, with the use of aggressive treatment with glucocorticoids and cyclophosphamide, the mortality associated with DAH in SLE is declining. 8, 34, 35 DAH is distinguished from acute lupus pneumonitis using sequential BAL. Acute lupus pneumonitis presents with similar clinical and radiographic features as DAH; however, it also has systemic symptoms typical of an SLE flare and may be the only manifestation of the initial presentation of SLE. 36 The histologic appearance of acute lupus pneumonitis is varied and includes diffuse alveolar damage, organizing pneumonia, nonspecifi c cellular pneumonitis, or a combination of these histologic patterns, but capillaritis is not present. 37 Immune complexes are frequently found in the lung. The deposition of immune complexes and the activation of complement within the lung are central to the development of parenchymal disease in SLE. 38 Methylprednisolone is recommended (1-2 mg/kg/d in divided doses ). High-dose pulse methylprednisolone (1 g given in divided doses for 3 days ) can be given to those with DAH or acute lupus pneumonitis. Escalating treatment in steroid-resistant DAH includes azathioprine, cyclophosphamide, or intravenous g globulin. The combination of high-dose intravenous methylprednisolone and cyclophosphamide anecdotally is the most effective combination. In refractory cases, plasmapheresis has been used; however, survival does not appear to be improved. 35, [39] [40] [41] In a patient with SLE who has established DAH, recurrences are to be expected. establishment of diagnosis, and aggressive treatment likely decreases the morbidity and mortality associated with untreated or unrecognized DAH.
1998. 66 Since then, the mechanism of the acute rejection with DAH has been studied further. [67] [68] [69] A necrotizing, pauciinflammatory septal capillary injury pattern was noted. Immunofl uorescent staining revealed a septal capillary deposition of antibodies specifi c for complement factors and immunoglobulin subtypes. 67 Differentiating between acute cellular rejection and posttransplant capillaritis requires tissue biopsy and can be found concomitantly in . 50% of cases. Isolated pulmonary capillaritis, however, is an infrequent occurrence (approximately 10% of all biopsies performed; M. Zamora, personal communication). Treatment consists of IV corticosteroids and plasmapheresis in severe cases. [69] [70] [71] [72] Bone Marrow Transplant Pulmonary complications develop in 30% to 60% of all bone marrow transplant recipients and are the cause of death in up to 60%. 73, 74 DAH occurs in approximately 5% of allogeneic and autologous recipients and has a reported mortality rate ranging from 50% to 100%. 7, 75 Of the recipients that develop DAH as a pulmonary complication and survive, the 6-month 76 mortality is 38%. 77 The frequency of DAH does not appear to vary signifi cantly with the type of hematopoietic stem cell transplant, with a reported frequency of 1% to 21% in autologous and 2% to 17% in allogeneic hematopoietic stem cell transplant recipients. 7 Risk factors for the development of DAH in bone marrow transplant recipients include older age, total body radiation, myeloablative conditioning regimens, and severe acute graft-vs-host disease. 7, 78 Clinically, these patients present with hemoptysis less frequently compared with other causes of DAH with a rate of approximately 15%. 76, 77 Protective strategies, such as reducing the intensity of the conditioning regimen, do not appear to decrease the risk of DAH. 7 The pathogenesis of DAH in bone marrow transplant recipients has yet to be clearly established, but it has been suggested that tissue injury, infl ammation, and the associated cytokine release play important roles. Lung biopsy reveals diffuse alveolar damage and DAH. 79 The majority of patients with DAH require mechanical ventilation and corticosteroids are the mainstay of treatment, although their effectiveness remains uncertain. 74, 78 Summary DAH is a clinicopathologic syndrome that results from a variety of conditions and should be considered a life-threatening event. Once believed to be a rare syndrome, DAH is being recognized with increasing frequency. A systematic approach to early recognition,
